Search tips
Search criteria 


Logo of aacPermissionsJournals.ASM.orgJournalAAC ArticleJournal InfoAuthorsReviewers
Antimicrob Agents Chemother. 1994 September; 38(9): 2134–2142.
PMCID: PMC284697

Sensitive and specific radioimmunoassay for fialuridine: initial assessment of pharmacokinetics after single oral doses to healthy volunteers.


Fialuridine (FIAU) is a halogen-substituted analog of thymidine that was undergoing clinical investigation as a drug for the treatment of chronic hepatitis B viral infection. However, clinical trials of FIAU were terminated after adverse events occurred following chronic oral administration. Prior to the termination of clinical trials, a sensitive assay was needed for the measurement of FIAU because of the anticipated low dose administered to patients. We therefore undertook the development of a radioimmunoassay (RIA). A specific antiserum was raised in rabbits following immunization with a 5'-O-hemisuccinate analog of FIAU coupled to keyhole limpet hemocyanin. Radiolabeled FIAU was synthesized by a destannylation procedure by using sodium [125I]iodide. We developed a competitive-binding procedure and used precipitation with polyethylene glycol as the method for separating the bound and free forms of FIAU. The RIA is sensitive (0.2 ng/ml), specific (negligible interference from known metabolites and endogenous nucleosides), and reproducible (interassay coefficients of variation range from 5 to 19.7% for serum controls). We used the RIA to assess the pharmacokinetics of FIAU in healthy adult volunteers following administration of a single 5-mg oral dose. The sensitivity of the RIA permitted the detection of a prolonged elimination phase for FIAU in healthy volunteers and dogs, with mean elimination half-lives of 29.3 and 35.3 h, respectively. We conclude the RIA is a valid method for the quantification of FIAU in biological fluids.

Full text

Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (1.7M), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Austin RK, Trefts PE, Hintz M, Connor JD, Kagnoff MF. Sensitive radioimmunoassay for the broad-spectrum antiviral agent ribavirin. Antimicrob Agents Chemother. 1983 Nov;24(5):696–701. [PMC free article] [PubMed]
  • Bubnis WA, Ofner CM., 3rd The determination of epsilon-amino groups in soluble and poorly soluble proteinaceous materials by a spectrophotometric method using trinitrobenzenesulfonic acid. Anal Biochem. 1992 Nov 15;207(1):129–133. [PubMed]
  • Chard T. Ammonium sulfate and polyethylene glycol as reagents to separate antigen from antigen-antibody complexes. Methods Enzymol. 1980;70(A):280–291. [PubMed]
  • Chou TC, Feinberg A, Grant AJ, Vidal P, Reichman U, Watanabe KA, Fox JJ, Philips FS. Pharmacological disposition and metabolic fate of 2'-fluoro-5-iodo-1-beta-D-arabinofuranosylcytosine in mice and rats. Cancer Res. 1981 Sep;41(9 Pt 1):3336–3342. [PubMed]
  • Cload PA. A review of the pharmacokinetics of zidovudine in man. J Infect. 1989 Jan;18 (Suppl 1):15–21. [PubMed]
  • Colacino JM, Lopez C. Efficacy and selectivity of some nucleoside analogs as anti-human cytomegalovirus agents. Antimicrob Agents Chemother. 1983 Oct;24(4):505–508. [PMC free article] [PubMed]
  • Colbert DL, Eremin SA, Landon J. The effect of fluorescein labels on the affinity of antisera to small haptens. J Immunol Methods. 1991 Jul 5;140(2):227–233. [PubMed]
  • Collins JM, Unadkat JD. Clinical pharmacokinetics of zidovudine. An overview of current data. Clin Pharmacokinet. 1989 Jul;17(1):1–9. [PubMed]
  • Cox S, Rudén U, Nagy K, Albert J, Holmberg V, Sandström E, Wahren B. Serum levels and catabolism of 3'-azido-3'-deoxythymidine in vivo measured using a specific radioimmunoassay. J Virol Methods. 1990 Oct;30(1):89–98. [PubMed]
  • Drew WL, Miner R, King D. Antiviral activity of FIAU (1-[2'deoxy-2'-fluoro-1-beta-D-arabinofuranosyl]-5-iodo-uridine) on strains of cytomegalovirus sensitive and resistant to ganciclovir. J Infect Dis. 1991 Jun;163(6):1388–1389. [PubMed]
  • Dudley RA, Edwards P, Ekins RP, Finney DJ, McKenzie IG, Raab GM, Rodbard D, Rodgers RP. Guidelines for immunoassay data processing. Clin Chem. 1985 Aug;31(8):1264–1271. [PubMed]
  • ERLANGER BF, BOREK F, BEISER SM, LIEBERMAN S. Steroid-protein conjugates. I. Preparation and characterization of conjugates of bovine serum albumin with testosterone and with cortisone. J Biol Chem. 1957 Oct;228(2):713–727. [PubMed]
  • ERLANGER BF, BOREK F, BEISER SM, LIEBERMAN S. Steroid-protein conjugates. II. Preparation and characterization of conjugates of bovine serum albumin with progesterone, deoxycorticosterone, and estrone. J Biol Chem. 1959 May;234(5):1090–1094. [PubMed]
  • Feinberg A, Leyland-Jones B, Fanucchi MP, Hancock C, Fox JJ, Watanabe KA, Vidal PM, Williams L, Young CW, Philips FS. Biotransformation and elimination of [2-14C]-1-(2-deoxy-2'-fluoro-beta-D -arabinofuranosyl)-5-iodocytosine in immunosuppressed patients with herpesvirus infections. Antimicrob Agents Chemother. 1985 May;27(5):733–738. [PMC free article] [PubMed]
  • Földes O, Uherová P, Mayer V. Plasma levels of the anti-HIV drug 3'-azido-2',3'-dideoxythymidine (AZT): determination by RIA and HPLC. Acta Virol. 1993 Apr-Jun;37(2-3):156–164. [PubMed]
  • Fourel I, Hantz O, Cova L, Allaudeen HS, Trepo C. Main properties of duck hepatitis B virus DNA polymerase: comparison with the human and woodchuck hepatitis B virus DNA polymerases. Antiviral Res. 1987 Nov;8(4):189–199. [PubMed]
  • Fourel I, Li J, Hantz O, Jacquet C, Fox JJ, Trépo C. Effects of 2'-fluorinated arabinosyl-pyrimidine nucleosides on duck hepatitis B virus DNA level in serum and liver of chronically infected ducks. J Med Virol. 1992 Jun;37(2):122–126. [PubMed]
  • Fourel I, Hantz O, Watanabe KA, Jacquet C, Chomel B, Fox JJ, Trepo C. Inhibitory effects of 2'-fluorinated arabinosyl-pyrimidine nucleosides on woodchuck hepatitis virus replication in chronically infected woodchucks. Antimicrob Agents Chemother. 1990 Mar;34(3):473–475. [PMC free article] [PubMed]
  • Gish DT, Kelly RC, Camiener GW, Wechter WJ. Nucleic acids. 11. Synthesis of 5'-esters of 1-beta-D-arabinofuranosylcytosine possessing antileukemic and immunosuppressive activity. J Med Chem. 1971 Dec;14(12):1159–1162. [PubMed]
  • Grant AJ, Feinberg A, Chou TC, Watanabe KA, Fox JJ, Philips FS. Incorporation of metabolites of 2'-fluoro-5-iodo-1-beta-D-arabinofuranosylcytosine into deoxyribonucleic acid of neoplastic and normal mammalian tissues. Biochem Pharmacol. 1982 Mar 15;31(6):1103–1108. [PubMed]
  • Hantz O, Allaudeen HS, Ooka T, De Clercq E, Trepo C. Inhibition of human and woodchuck hepatitis virus DNA polymerase by the triphosphates of acyclovir, 1-(2'-deoxy-2'-fluoro-beta-D-arabinofuranosyl)-5-iodocytosine and E-5-(2-bromovinyl)-2'-deoxyuridine. Antiviral Res. 1984 Aug;4(4):187–199. [PubMed]
  • Langtry HD, Campoli-Richards DM. Zidovudine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy. Drugs. 1989 Apr;37(4):408–450. [PubMed]
  • Lopez C, Watanabe KA, Fox JJ. 2'-fluoro-5-iodo-aracytosine, a potent and selective anti-herpesvirus agent. Antimicrob Agents Chemother. 1980 May;17(5):803–806. [PMC free article] [PubMed]
  • Macilwain C. NIH, FDA seek lessons from hepatitis B drug trial deaths. Nature. 1993 Jul 22;364(6435):275–275. [PubMed]
  • Morse GD, Portmore A, Olson J, Taylor C, Plank C, Reichman RC. Multiple-dose pharmacokinetics of oral zidovudine in hemophilia patients with human immunodeficiency virus infection. Antimicrob Agents Chemother. 1990 Mar;34(3):394–397. [PMC free article] [PubMed]
  • Morse GD, Shelton MJ, O'Donnell AM. Comparative pharmacokinetics of antiviral nucleoside analogues. Clin Pharmacokinet. 1993 Feb;24(2):101–123. [PubMed]
  • Okabayashi T, Mihara S, Repke DB, Moffatt JG. A radioimmunoassay for 1-beta-D-arabinofuranosylcytosine. Cancer Res. 1977 Feb;37(2):619–624. [PubMed]
  • Okabayashi T, Mihara S, Repke DB, Moffatt JG. A radioimmunoassay for 1-beta-D-arabinofuranosyluracil with reference to cross-reactivity of 1-beta-D-arabinofuranosylcytosine with an antibody. Cancer Res. 1977 Sep;37(9):3132–3135. [PubMed]
  • Okabayashi T, Moffatt JG. Radioimmunoassay of 1-beta-D-arabinofuranosylcytosine. Methods Enzymol. 1982;84:470–483. [PubMed]
  • Pauillac S, Halmos T, Labrousse H, Antonakis K, Avrameas S. Production of highly specific monoclonal antibodies to monensin and development of a microELISA to detect this antibiotic. J Immunol Methods. 1993 Sep 15;164(2):165–173. [PubMed]
  • Philips FS, Feinberg A, Chou TC, Vidal PM, Su TL, Watanabe KA, Fox JJ. Distribution, metabolism, and excretion of 1-(2-fluoro-2-deoxy-beta-D- arabinofuranosyl)thymine and 1-(2-fluoro-2-deoxy-beta-D-arabinofuranosyl)-5- iodocytosine. Cancer Res. 1983 Aug;43(8):3619–3627. [PubMed]
  • Quinn RP, de Miranda P, Gerald L, Good SS. A sensitive radioimmunoassay for the antiviral agent BW248U [9-(2-hydroxyethoxymethyl)guanine]. Anal Biochem. 1979 Oct 1;98(2):319–328. [PubMed]
  • Quinn RP, Orban B, Tadepalli S. Radioimmunoassay for Retrovir, an anti-human immunodeficiency virus drug. J Immunoassay. 1989;10(2-3):177–189. [PubMed]
  • Rodbard D. Statistical estimation of the minimal detectable concentration ("sensitivity") for radioligand assays. Anal Biochem. 1978 Oct 1;90(1):1–12. [PubMed]
  • Sato T, Morozumi M, Kodama K, Kuninaka A, Yoshino H. Sensitive radioimmunoassay for cytarabine and uracil arabinoside in plasma. Cancer Treat Rep. 1984 Nov;68(11):1357–1366. [PubMed]
  • Schreiber R, Raso V. Radioimmunoassay for the detection and quantitation of 5-fluorodexoyuridine. Cancer Res. 1978 Jul;38(7):1889–1892. [PubMed]
  • Shimada N, Ueda T, Yokoshima T, Oh-Ishi J, Oh-oka T. A sensitive and specific radioimmunoassay for 1-beta-D-arabino-furanosylcytosine. Cancer Lett. 1984 Sep;24(2):173–178. [PubMed]
  • Snyder SL, Sobocinski PZ. An improved 2,4,6-trinitrobenzenesulfonic acid method for the determination of amines. Anal Biochem. 1975 Mar;64(1):284–288. [PubMed]
  • Staschke KA, Colacino JM, Mabry TE, Jones CD. The in vitro anti-hepatitis B virus activity of FIAU [1-(2'-deoxy-2'-fluoro-1-beta-D-arabinofuranosyl-5-iodo)uracil] is selective, reversible, and determined, at least in part, by the host cell. Antiviral Res. 1994 Jan;23(1):45–61. [PubMed]
  • Sterzycki RZ, Ghazzouli I, Brankovan V, Martin JC, Mansuri MM. Synthesis and anti-HIV activity of several 2'-fluoro-containing pyrimidine nucleosides. J Med Chem. 1990 Aug;33(8):2150–2157. [PubMed]
  • Stretcher BN. State-of-the-art of zidovudine monitoring. J Clin Lab Anal. 1991;5(1):60–68. [PubMed]
  • Vallejo RP, Bogus ER, Mumma RO. Effects of hapten structure and bridging groups on antisera specificity in parathion immunoassay development. J Agric Food Chem. 1982 May-Jun;30(3):572–580. [PubMed]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)